Lexicon Pharma (LXRX) Tops Q1 EPS by 3c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.54 --0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
STEL, WF, CWBC, More
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
STEL, WF, CWBC, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.40), $0.03 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $25.21 million versus the consensus estimate of $23.43 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- Civeo (CVEO) Misses Q1 EPS by 9c, provides guidance
- Sensient Technologies (SXT) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
